{"id":48150,"date":"2015-05-11T15:10:43","date_gmt":"2015-05-11T19:10:43","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?post_type=news&#038;p=48150"},"modified":"2015-06-16T12:13:04","modified_gmt":"2015-06-16T12:13:04","slug":"prominent-harvard-cardiologist-moves-to-google-x-to-head-large-study","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2015\/05\/11\/prominent-harvard-cardiologist-moves-to-google-x-to-head-large-study\/","title":{"rendered":"Prominent Harvard Cardiologist Moves to Google X to Head Large Study"},"content":{"rendered":"<p>Here&#8217;s\u00a0a clear sign of the ascending role of digital\/precision\/personalized medicine: a prominent cardiologist has left a top academic and clinical position in Boston to run\u00a0a large, innovative study in Silicon Valley. Jessica Mega was widely perceived as a rising star at Harvard Medical School and the Brigham and Women&#8217;s Hospital. She has now joined\u00a0Google\u00a0X,\u00a0Google&#8217;s\u00a0research arm, where she will\u00a0head up the much publicized\u00a0Baseline Study.<\/p>\n<p>&#8220;I&#8217;m jealous,&#8221; said one academic cardiologist at a top hospital, upon hearing the news.<\/p>\n<p>Baseline is one of the ambitious projects undertaken by the\u00a0life sciences division of\u00a0Google\u00a0X.\u00a0<a href=\"http:\/\/www.wsj.com\/articles\/google-to-collect-data-to-define-healthy-human-1406246214\">First announced last year<\/a>, the Baseline Study is designed &#8220;to understand what it means to be healthy, down to the molecular and cellular level,&#8221; according to a\u00a0Google\u00a0press statement. In its\u00a0first small pilot phase the study is collecting\u00a0genetic and molecular information on 175 people. The researchers aim to employ &#8220;powerful software algorithms and large amounts of computing power to query enormous and complex data sets to find connections that no one has been able to probe before.&#8221;\u00a0Google\u00a0X has teamed with researchers at Stanford and Duke to design and conduct the larger study which will enroll thousands of patients and involve an unprecedented\u00a0quantity\u00a0of data.<\/p>\n<p>Mega gained considerable attention as\u00a0a senior investigator with the TIMI Study Group, where she played a leading role in several important clinical trials, including ATLAS ACS-TIMI 46 and ATLAS ACS 2-TIMI 51 with rivaroxaban (Xarelto,\u00a0Johnson &amp; Johnson). She \u00a0was the principal investigator of\u00a0the ELEVATE-TIMI 56 trial, which studied\u00a0escalating doses of clopidogrel based on CYP2C19 genotype.<\/p>\n<p>Google X says that the study &#8220;is intended as a contribution to science; it\u2019s not intended to generate a new product at Google,&#8221; though it may &#8220;unlock lots of ideas for future projects, not just at Google but across the health and technology industries.&#8221; Google says the results of the study will be made available to qualified researchers for their own use.<\/p>\n<p>Bob Harrington, chairman of Stanford&#8217;s Department of Medicine, said that he was &#8220;thrilled by Google&#8217;s recruitment of Jessica to join the team working with our group and Duke. She was an inspired choice: smart, insightful, experienced, great communicator etc. She understands the science and the operations of clinical research given her TIMI background. In addition to her role at Google, we hope to get her engaged in other clinical and research activities on the Stanford campus in our department. Finally, we are pleased to welcome her back home to the Farm as she is a Stanford grad!&#8221;<\/p>\n<p>Robert Califf, who played a key role in bringing\u00a0the trial to Duke, is now the\u00a0Deputy Commissioner for Medical Products and Tobacco at the FDA. &#8220;Dr. Mega has all the skills and temperament to lead this effort for Google, which will break new ground for precision medicine and complement the Precision Medicine Initiative. Her scientific knowledge, experience in clinical trials, and positive personality are a great fit,&#8221; said Califf.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Here&#8217;s\u00a0a clear sign of the ascending role of digital\/precision\/personalized medicine: a prominent cardiologist has left a top academic and clinical position in Boston to run\u00a0a large, innovative study in Silicon Valley. Jessica Mega was widely perceived as a rising star at Harvard Medical School and the Brigham and Women&#8217;s Hospital. She has now joined\u00a0Google\u00a0X,\u00a0Google&#8217;s\u00a0research arm, [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[2565,270,2564,2484],"class_list":["post-48150","post","type-post","status-publish","format-standard","hentry","category-general","tag-baseline-study","tag-genetics","tag-google","tag-precision-medicine"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/48150","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=48150"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/48150\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=48150"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=48150"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=48150"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}